However, our study herein strongly implicates the potential for combination therapies targeting Ron, or more specifically β-catenin signaling, and treatment with vitamin D3 or potent vitamin D3 analogs that may benefit patients with aggressive, Ron-mediated breast cancer. Here, MST1R is linked to breast carcinoma.